TY - JOUR
T1 - Interindividual and Intraindividual Variability in Labetalol Pharmacokinetics
AU - Awni, W. M.
AU - Skaar, D. J.
AU - Schwenk, M. H.
AU - Sirgo, M. A.
AU - Plachetka, J. R.
AU - Matzke, G. R.
PY - 1988/4
Y1 - 1988/4
N2 - The between‐subject and within‐subject variability in the pharmacokinetics of labetalol at steady state were determined. Sixteen nonobese normal volunteers (mean age, 27 years) received five different formulations of labetalol orally on five different occasions every 12 hours for five doses. A 7‐day washout separated each administration phase. Plasma concentration‐time data for labetalol were obtained over the 24‐hour period after the fifth dose in each phase. Labetalol concentrations in plasma were measured using high‐performance liquid chromatography (HPLC). Pharmacokinetic parameters for each subject after each study phase were estimated. The mean Vβ/F, Vdss/F, TBC/F, t1/2β, and AUC0r for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 μg ṁ hr/L, respectively, indicating large interindividual variability. Considerable intraindividual variability in each of the pharmacokinetic parameters was also observed. These data indicate that a larger number of subjects will be required to detect “significant” differences in the disposition of labetalol. 1988 American College of Clinical Pharmacology
AB - The between‐subject and within‐subject variability in the pharmacokinetics of labetalol at steady state were determined. Sixteen nonobese normal volunteers (mean age, 27 years) received five different formulations of labetalol orally on five different occasions every 12 hours for five doses. A 7‐day washout separated each administration phase. Plasma concentration‐time data for labetalol were obtained over the 24‐hour period after the fifth dose in each phase. Labetalol concentrations in plasma were measured using high‐performance liquid chromatography (HPLC). Pharmacokinetic parameters for each subject after each study phase were estimated. The mean Vβ/F, Vdss/F, TBC/F, t1/2β, and AUC0r for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 μg ṁ hr/L, respectively, indicating large interindividual variability. Considerable intraindividual variability in each of the pharmacokinetic parameters was also observed. These data indicate that a larger number of subjects will be required to detect “significant” differences in the disposition of labetalol. 1988 American College of Clinical Pharmacology
UR - http://www.scopus.com/inward/record.url?scp=0024215057&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024215057&partnerID=8YFLogxK
U2 - 10.1002/j.1552-4604.1988.tb03156.x
DO - 10.1002/j.1552-4604.1988.tb03156.x
M3 - Article
C2 - 3392232
AN - SCOPUS:0024215057
SN - 0091-2700
VL - 28
SP - 344
EP - 349
JO - The Journal of Clinical Pharmacology
JF - The Journal of Clinical Pharmacology
IS - 4
ER -